Cargando…
Small molecule tyrosine kinase inhibitors in pancreatic cancer
Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for advanced pancreatic cancer since 1996. Tyrosine kinase inhibitors represent a newer generation of chemotherapeutic agents targeting specific tumor pathways associated with carcinogenesis...
Autores principales: | Gupta, Sachin, El-Rayes, Bassel F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727890/ https://www.ncbi.nlm.nih.gov/pubmed/19707451 |
Ejemplares similares
-
HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
por: Spector, Neil, et al.
Publicado: (2007) -
New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
por: Lin, Nancy U, et al.
Publicado: (2004) -
Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
por: Hojjat-Farsangi, Mohammad
Publicado: (2014) -
Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?
por: Rendell, Aimee, et al.
Publicado: (2022) -
Mirage or long-awaited oasis: reinvigorating T-cell responses in pancreatic cancer
por: Ware, Michael Brandon, et al.
Publicado: (2020)